FRONT PAGE AMPYRA AUBAGIO AVONEX BETASERON COPAXONE EXTAVIA
Stan's Angels MS News Channel on YouTube GILENYA NOVANTRONE REBIF RITUXAN TECFIDERA TYSABRI
 Daily News for Neuros, Nurses & Savvy MSers: 208,152 Viewers, 8,368 Stories & Studies
Click Here For My Videos, Advice, Tips, Studies and Trials.
Timothy L. Vollmer, MD
Department of Neurology
University of Colorado Health Sciences Center Professor

Co-Director of the RMMSC at Anschutz Medical Center

Medical Director-Rocky Mountain MS Center
Click here to read my columns
Brian R. Apatoff, MD, PhD
Multiple Sclerosis Institute
Center for Neurological Disorders

Associate Professor Neurology and Neuroscience,

Weill Medical College of Cornell University

Clinical Attending in Neurology,
New York-Presbyterian Hospital
CLICK ON THE RED BUTTON BELOW
You'll get FREE Breaking News Alerts on new MS treatments as they are approved
MS NEWS ARCHIVES: by week

HERE'S A FEW OF OUR 6000+ Facebook & MySpace FRIENDS
Timothy L. Vollmer M.D.
Department of Neurology
University of Colorado Health Sciences Center
Co-Director of the RMMSC at Anschutz Medical Center
and
Medical Director-Rocky Mountain MS Center


Click to view 1280 MS Walk photos!

"MS Can Not
Rob You of Joy"
"I'm an M.D....my Mom has MS and we have a message for everyone."
- Jennifer Hartmark-Hill MD
Beverly Dean

"I've had MS for 2 years...this is the most important advice you'll ever hear."
"This is how I give myself a painless injection."
Heather Johnson

"A helpful tip for newly diagnosed MS patients."
"Important advice on choosing MS medication "
Joyce Moore


This page is powered by Blogger. Isn't yours?

Sunday

 

Oral MS Drugs Effective in Phase III Trials

Two oral drugs under investigation for multiple sclerosis reduced relapse rates and delayed onset of disability in separate trials reported online this week in the New England Journal of Medicine.

Fingolimod, a novel agent also known as FTY-720, was more effective than both placebo and the standard of care for MS, interferon-beta-1a (Avonex), in two independent trials.....full report in MedPage Today

Labels:


 

Reform Promises to Lower Bills for Chronic Illness


Women with chronic illnesses such as rheumatoid arthritis and MS often have trouble affording the care they need, even when they have health insurance. Advocates hope a variety of health-reform provisions will bring relief....full story in Womens eNews

 

European Drugs Watchdog Finds Benefits Of Tysabri Continue To Outweigh Risks

The European Medicines Agency (EMA) has finalised a review of Tysabri (natalizumab) and the risk of progressive multifocal leukoencephalopathy (PML), a rare brain infection caused by the JC virus.

The Agency's Committee for Medicinal Products for Human Use (CHMP) has concluded that the risk of developing PML increases after two years of use of Tysabri although this risk remains low.

It also stated, however, that the benefits of the medicine continue to outweigh its risks for patients with highly active relapsing-remitting multiple sclerosis, for whom there are few treatment options available.

As a result of the review, the Committee recommended a number of measures be put in place to ensure that patients and doctors are fully aware of the risks of PML. ....full report in Medical News Today

Labels: , ,


 

Pills To Treat MS Could Be Round The Corner

Clinical trial results for the tablets being developed for multiple sclerosis (MS) will be published in the latest issue of the New England Journal of Medicine. .....full report in Medical News Today

 

New Multiple Sclerosis Drug Significantly Reduces Relapse And Deterioration

A new drug for multiple sclerosis promises to change the lives of the 100,000 people in the UK who have the condition, say researchers at Queen Mary, University of London. ....full report in Medical News Today

 

PROLOR Biotech Reports Positive Results From Comparative Study Of Its Longer-Acting Version Of Multiple Sclerosis Drug Interferon Beta In Primates

PROLOR Biotech, Inc., (OTC Bulletin Board: PBTH) reported positive results from a comparative study in primates of its longer-acting version of the multiple sclerosis drug interferon beta (IFN-beta-1a-CTP, referred to as IFN-beta-CTP). The study was designed to measure the potential increase in durability (half-life), overall drug exposure (AUC) and biological potency of PROLOR's long-acting CTP-modified human interferon beta when compared with commercially available interferon beta. Interferon-beta-1a (referred to as IFN-beta), which is indicated for the treatment of multiple sclerosis (MS), is currently marketed by Merck Serono as Rebif® and by Biogen Idec as Avonex®, with combined annual sales estimated at more than $3 billion worldwide......full report in Medical News Today

Labels: ,


 

Regis Technologies Passes FDA Pre-Approval Inspection For Acorda Therapeutics' Approved Multiple Sclerosis Drug, Ampyra™

Regis Technologies, Inc., a leading provider of cGMP and non-GMP synthesis and separations services for active pharmaceutical ingredients (APIs) and intermediates, announced it has received an Establishment Inspection Report (EIR) from the U.S. Food and Drug Administration (FDA) stating that Regis passed the FDA's pre-approval inspection (PAI) for its manufacture of 4-Aminopyridine the active ingredient in Ampyra™.

Acorda Therapeutics' drug, Ampyra™, was approved by the FDA on January 22, 2010, as a treatment to improve walking in patients with multiple sclerosis (MS). This was demonstrated by an increase in walking speed. The FDA inspected Regis's facility for seven days in April and May 2009. The EIR and PAI approval was issued in November, 2009.......full report in Medical News Today

Labels: ,


 

MS Society Calls On Stem Cell Researchers For Grant Applications

The MS Society has called for researchers and scientists to come forward with research projects investigating the potential benefit of stem cells in multiple sclerosis (MS).

A new partnership between the MS Society and the UK Stem Cell Foundation has levered £1million to be specifically ring-fenced for translational, pre-clinical and clinical trials.

Currently there are limited treatment options available for people with MS, especially for progressive forms of the condition, and the identification and development of disease modifying therapies for MS remains a major priority for the MS Society.

At an International Stem Cells and MS Consensus Meeting, organised by the MS Society and held in London in May 2009, it was announced that a concerted effort in stem cell research and clinical trials of stem cell therapies for MS is now needed.

The MS Society and UKSCF partnership was set up as a direct result of this work
Medical News Today

Wednesday

 

Saskatoon City Hospital Foundation: Saskatchewan Campaign Launched to Fight Multiple Sclerosis

Full story in Market Wire

 

Acorda/Biogen Idec: pricing will determine success of symptomatic MS therapy

The FDA has approved Acorda's Ampyra for the symptomatic treatment of multiple sclerosis, making it the first therapeutic option approved to address walking impairments experienced by patients with the disease. However, despite favorable efficacy data, prescriptions are likely to be limited by price concerns and the risk of seizures. - report in Trading Markets.com

Labels: ,


 

What’s Up With Oral Drugs for Multiple Sclerosis?

I feel a little negligent. I heard back in December that Merck KGaA's oral drug, cladribine, had not been approved by the FDA for use in multiple sclerosis. I mentally shrugged and didn't do any further research into the situation (mainly because there was so much excitement about the CCSVI and MS thing). - story in About.com: Multiple Sclerosis

 

New multiple sclerosis drug helps some patients walk

Ampyra, the first new drug introduced in six years for the symptoms of multiple sclerosis (MS), has been approved by the U.S. Food and Drug Administration. - story in CantonRep.com

Labels: ,


 

Biogen Idec Begins Phase 1 Study of Multiple Sclerosis Treatment (BIIB)

Biogen Idec (NASDAQ:BIIB) has begun a small Phase 1 study of an experimental drug, dubbed BIIB033, for treatment of Multiple Sclerosis, a chronic, inflammatory condition that occurs when the body attacks its own myelin, which affects 400,000 people in the U.S.; current treatments can slow damage to the central nervous system, but not help repair it. - in SmarTrend News and Market Research

 

What's new for 'Multiple Sclerosis' on PubMed

Widespread cortical thinning characterizes patients with MS with mild cognitive impairment. - A widespread pattern of cortical thinning characterizes patients with cognitive dysfunction, suggesting such dysfunction as expression of a more aggressive and widespread cortical pathology. - Neurology. 2010 Jan 26;74(4):321-8. - in PubMed

Fatigue in multiple sclerosis: Mechanisms and management. - Clin Neurophysiol. 2010 Jan 23. [Epub ahead of print] in PubMed

Alemtuzumab and multiple sclerosis: therapeutic application. - Expert Opin Biol Ther. 2010 Jan 22. [Epub ahead of print] - in PubMed


Go to Newer News Go to Older News